ABPI asks UK government to review VPAS as clawback will hit 26.5% of sales revenue in 2023
In 2023 manufacturers of branded medicines will be required to return almost £3.3bn in sales revenue to the government under the 2019 Voluntary scheme for branded medicines, pricing and access (VPAS), according to the Association of the British Pharmaceutical Industry (ABPI).
